These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 24379249

  • 1. [Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment].
    Podhorecka M, Macheta A.
    Postepy Hig Med Dosw (Online); 2013 Nov 25; 67():1083-9. PubMed ID: 24379249
    [Abstract] [Full Text] [Related]

  • 2. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R, de Thé H.
    Int J Hematol; 2010 Jun 25; 91(5):742-7. PubMed ID: 20455087
    [Abstract] [Full Text] [Related]

  • 3. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD.
    Oncologist; 2002 Jun 25; 7 Suppl 1():1-13. PubMed ID: 11961204
    [Abstract] [Full Text] [Related]

  • 4. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D, UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.
    Lancet Oncol; 2015 Oct 25; 16(13):1295-305. PubMed ID: 26384238
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29; 362(1482):959-71. PubMed ID: 17317642
    [Abstract] [Full Text] [Related]

  • 6. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D, Nasr R, de The H.
    Int J Biochem Cell Biol; 2007 Jun 29; 39(6):1063-70. PubMed ID: 17468032
    [Abstract] [Full Text] [Related]

  • 7. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G.
    Curr Pharm Biotechnol; 2013 Jun 29; 14(9):849-58. PubMed ID: 24433507
    [Abstract] [Full Text] [Related]

  • 8. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
    Strehl S, König M, Boztug H, Cooper BW, Suzukawa K, Zhang SJ, Chen HY, Attarbaschi A, Dworzak MN.
    Leukemia; 2013 Jul 29; 27(7):1606-10. PubMed ID: 23271512
    [No Abstract] [Full Text] [Related]

  • 9. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D, Oniashvili N, Parnes D, Klein A, Muchtar E, Yeshaya J, Aviram A, Rabizadeh E, Raanani P.
    Cancer Genet; 2015 Nov 29; 208(11):575-9. PubMed ID: 26471811
    [Abstract] [Full Text] [Related]

  • 10. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Nov 29; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 11. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y.
    Leuk Lymphoma; 2004 Apr 29; 45(4):639-48. PubMed ID: 15160934
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L, Mohassel L.
    Am J Health Syst Pharm; 2009 Nov 01; 66(21):1913-8. PubMed ID: 19850784
    [Abstract] [Full Text] [Related]

  • 13. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
    Komatsu N.
    Int J Hematol; 2014 Jul 01; 100(1):16-7. PubMed ID: 24912657
    [No Abstract] [Full Text] [Related]

  • 14. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    Ng Liet Hing M, Ryland GL, Nguyen T, Tiong IS, Dun K, Ninkovic S, Nedumannil R, Westerman DA, Blombery PA, Chan KL, Bajel A.
    Br J Haematol; 2023 Aug 01; 202(4):893-896. PubMed ID: 37280781
    [No Abstract] [Full Text] [Related]

  • 15. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T, Sawaki K.
    J Pharmacol Sci; 2014 Aug 01; 126(3):179-85. PubMed ID: 25319615
    [Abstract] [Full Text] [Related]

  • 16. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K, Ghavamzadeh A, Jahani M, Mousavi A, Iravani M, Rostami S, Ghaffari H, Hosseini R, Jalili M.
    Arch Iran Med; 2011 May 01; 14(3):167-9. PubMed ID: 21529103
    [Abstract] [Full Text] [Related]

  • 17. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
    Mikoshiba M, Ohashi K, Takei N, Okuyama Y, Maeda Y, Hiruma K, Akiyama H, Fukuhara O, Takeshita A, Sakamaki H.
    Int J Hematol; 2002 Jan 01; 75(1):104-6. PubMed ID: 11843281
    [No Abstract] [Full Text] [Related]

  • 18. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul 01; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 19. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
    Zhao WL, Chen SJ, Shen Y, Xu L, Cai X, Chen GQ, Shen ZX, Chen Z, Wang ZY.
    Leuk Lymphoma; 2001 Jul 01; 42(6):1265-73. PubMed ID: 11911407
    [Abstract] [Full Text] [Related]

  • 20. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin, Huang MJ, Chang IY, Lin WY, Sheu YT.
    Leuk Lymphoma; 2000 Jun 01; 38(1-2):195-8. PubMed ID: 10811463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.